News

PE Hub6h
Accel-KKR, Carlyle, Vistria target home care software; Bain Capital, Bristol Myers Squibb launch autoimmune biopharma biz
Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...
Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript
Bristol-Myers Squibb Company ( NYSE: BMY) Q2 2025 Earnings Conference Call July 31, 2025 8:00 AM ET ...
Bristol-Myers Squibb raises 2025 revenue guidance by $700M as new launches and partnerships accelerate growth trajectory
Discover Bristol-Myers Squibb's Q2 2025 earnings insights: 17% growth, new partnerships, and raised guidance signal strong performance and a ...
Bristol-Myers Squibb Company (NYSE:BMY) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript July 31, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $1.46, expectations were $1.07. Operator: Good day, and welcome to the ...
Treasury & Risk23h
New Cash Leadership Office Builds a Working Capital Culture at BMS
Congratulations to Bristol Myers Squibb on winning the 2025 Gold Alexander Hamilton Award in Working Capital Management!
Precision Medicine Online23h
BMS Focused on 'Needle-Moving' Oncology Therapies as Opdivo Growth Slows
The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...
Bristol Myers Squibb Cuts Full-Year Adjusted View, but Raises Revenue Expectations
Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...
Bristol-Myers Squibb (BMY) Sees Healthy Momentum in Growth Portfolio in Q2 2025
Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 31, the company reported results for Q2 2025, wherein it saw healthy momentum throughout its ...